scholarly journals Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?

2018 ◽  
Vol 142 (4) ◽  
pp. 480-489 ◽  
Author(s):  
Greta Alì ◽  
Rossella Bruno ◽  
Mauro Savino ◽  
Riccardo Giannini ◽  
Serena Pelliccioni ◽  
...  

Context.— Patients with non–small cell lung cancer harboring ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 (ROS1), and ret proto-oncogene (RET) gene rearrangements can benefit from specific kinase inhibitors. Detection of fusion genes is critical for determining the best treatment. Assessing rearrangements in non–small cell lung cancer remains challenging, particularly for lung cytology. Objective.— To examine the possible application of the multiplex, transcript-based NanoString system (NanoString Technologies, Seattle, Washington) in the evaluation of fusion genes in lung adenocarcinoma samples. Data Sources.— This study is a narrative literature review. Studies about NanoString, gene fusions, and lung adenocarcinoma were collected from PubMed (National Center for Biotechnology Information, Bethesda, Maryland). We found 7 articles about the application of the NanoString system to detect fusion genes on formalin-fixed, paraffin-embedded tumor tissues and one article evaluating the adequacy of lung cytologic specimens for NanoString gene expression analysis. Conclusions.— To maximize the yield of molecular tests on small lung biopsies, the NanoString nCounter system has been suggested to detect fusion genes. NanoString fusion gene assays have been successfully applied on formalin-fixed, paraffin-embedded tissues. Although there are only a few studies available, the application of NanoString assays may also be feasible in lung cytology. According to available data, the NanoString system could strengthen the routine molecular characterization of lung adenocarcinoma.

2021 ◽  
pp. 101745
Author(s):  
Tamyres Mingorance Carvalho ◽  
Renata Montoro Dourado ◽  
Sueli Massumi Nakatani ◽  
Cesar Augusto Barros Duarte ◽  
Sergio Ossamu Ioshii ◽  
...  

Diagnostics ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 13
Author(s):  
Odharnaith O’Brien ◽  
Mark Wright ◽  
Cathal O’Brien ◽  
Orla Geoghegan ◽  
Niamh Leonard ◽  
...  

MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.


Sign in / Sign up

Export Citation Format

Share Document